Stay updated on IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check27 days agoChange DetectedA banner announces NIH website changes and says the agency is transitioning from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference0.5%

- Check34 days agoChange DetectedThe site footer’s software revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.1%

- Check41 days agoChange DetectedThe website footer revision identifier changed from v3.7.0 to v3.7.1, while the study record history remains unchanged.SummaryDifference0.1%

- Check62 days agoChange DetectedA new revision entry v3.7.0 was added to the study record history, and the previous entry v3.6.6 was removed. This updates the page’s revision history to reflect the latest version of the record.SummaryDifference0.1%

- Check83 days agoChange DetectedThe record history now lists a new latest revision: v3.6.6, replacing v3.6.5. This indicates a minor update to the study record history.SummaryDifference0.1%

Stay in the know with updates to IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.